Earning the honor of first biotechnology company to conduct an IPO this year, Eyetech Pharmaceuticals Inc. raised $136.5 million and watched its stock skyrocket on Friday, trading up 54.3 percent from its opening price. (BioWorld Today)

Despite a failed trial last year, Antegren now has garnered some positive Phase III data, meeting its primary endpoint by maintaining a response in Crohn's disease patients. (BioWorld Today)

With hopes of raising $86.25 million to advance two cancer drugs and a preclinical candidate for heart failure, Cytokinetics Inc. filed for its initial public offering. (BioWorld Today)

In the second biotech public offering of the year, Dendreon Corp. raised $130.7 million, money that will be used to fund clinical trials and develop a commercial infrastructure for Provenge. (BioWorld Today)

One year before a potential launch, Inex Pharmaceuticals Corp. found a North American partner - Enzon Pharmaceuticals Inc. - for its cancer drug Onco TCS. (BioWorld Today)

ILEX Oncology Inc.'s drug eflornithine (DFMO) failed to reach statistical significance in a Phase III trial with superficial bladder cancer patients, resulting in the company's decision to discontinue development. (BioWorld Today)